SCANDION ONCOLOGY A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.22 SEK | -17.91% |
|
-28.10% | -94.49% |
| May. 22 | Transcript : Scandion Oncology A/S, Q1 2024 Earnings Call, May 22, 2024 | |
| May. 22 | Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 7.19M 75.44M |
|---|---|---|---|---|---|
| Net income 2022 | -76M -798M | Net income 2023 | -39M -409M | EV / Sales 2022 | - |
| Net cash position 2022 | 77.6M 814M | Net cash position 2023 | 26.52M 278M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.01
x | P/E ratio 2023 |
-2.77
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on Scandion Oncology A/S
More press releases
| 1 day | -17.91% | ||
| 1 week | -28.10% | ||
| Current month | -24.14% | ||
| 1 month | -65.08% | ||
| 3 months | -90.98% | ||
| 6 months | -94.20% | ||
| Current year | -94.49% |
1 week
0.20
0.32
1 month
0.200.70
Current year
0.205.64
1 year
0.205.64
3 years
0.2020.85
5 years
0.2075.00
10 years
0.2075.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 23-01-01 | |
Jan Stenvang
FOU | Founder | - | 16-12-31 |
Johnny Stilou
DFI | Director of Finance/CFO | 57 | 21-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 22-03-31 | |
| Director/Board Member | 69 | 18-05-06 | |
Martin Møller
CHM | Chairman | 49 | 21-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-04 | 0.22 | -17.91% | 381 715 |
| 24-07-03 | 0.268 | +3.08% | 144,908 |
| 24-07-02 | 0.26 | -10.34% | 288,746 |
| 24-07-01 | 0.29 | 0.00% | 79,637 |
| 24-06-28 | 0.29 | -5.23% | 125,177 |
Delayed Quote Nasdaq Stockholm, July 04, 2024 at 12:00 pm EDT
More quotes
Scandion Oncology A/S is a manufacturer of biological products. The Company was founded in May 2017 and is located in Copenhagen, Denmark. It focuses on modern onclogy, the treatment of cancers that have developed resistance to chemotherapy.
Calendar
2024-08-28
- Q2 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -94.49% | 1.04M | |
| +15.58% | 121B | |
| +16.60% | 110B | |
| +17.73% | 25.93B | |
| -24.33% | 19.27B | |
| -19.35% | 16.01B | |
| -17.95% | 15.66B | |
| -48.32% | 14.89B | |
| +58.78% | 14.47B | |
| +4.91% | 13.91B |
- Stock Market
- Equities
- SCOL Stock
